Survodutide
An investigational glucagon / GLP-1 receptor dual agonist.
Investigational / no FDA-approved-treatment claim
An investigational glucagon / GLP-1 receptor dual agonist.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Purported uses, not established benefits
Proposed uses include weight reduction in people with obesity.
The 2026 SYNCHRONIZE-1 trial reports weight reduction in adults without diabetes and frequent gastrointestinal adverse events. Its investigational product and study population must not be equated with research-chemical products.
Evidence and source limits
The source linked here describes research or investigational use. It does not establish an FDA-approved indication for this compound or for a research-chemical product. A claimed use is not an established benefit.
Product identity, purity, route, safety and suitability remain separate questions. Research-purpose-only labeling does not authorize human use. This note provides no dosing, preparation or purchase guidance.
Original source: Survodutide ↗
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.